KERUN BIOPHARM
RESEARCH AND DEVELOPMENT
-
OPHTHALMIC DRUGS
Focusing on the development of ophthalmic biological macromolecular drugs, the layout on the product pipeline covers fundus retinal vascular diseases, dry eye, keratitis, non infectious uveitis and other diseases in the field of ocular surface. Develop multiple drugs for one disease. One drug should have iterative drugs as much as possible to ensure the success rate of development -
OTHER PROTEIN DRUGS
At present, the company focuses on ophthalmic treatment products, but also has product layout in the fields of tumor and metabolic diseases, such as recombinant carboxypeptidase G2, which is expected to become a conventional compatible drug for the treatment of osteosarcoma, innovative long-term ADC drugs for the treatment of leukemia and long-term recombinant growth hormone for the treatment of growth and development defects. Compared with the listed products, these drugs not only have lower production costs, but also learn from the advantages of the first mover products, analyze their disadvantages, improve the design, and improve the effectiveness and safety of the drugs
NEWS
GATHERING ELITES
{"imgUrl":"https://koss.iyong.com/swift/v1/iyong_public/iyong_3056350420603137/image/20220419/1650330595894006315.jpg","origWidth":540,"origHeight":188,"hotAreaArr":[],"textBtnArr":[],"textBlockArr":[{"left":41.5,"top":30,"width":461,"height":150,"content":"
Kerun takes talent construction as the core, constantly attracts talents and encourages innovation.
Here, you get not only a job, but also a platform to give full play to your potential and realize your personal value.
Kerun takes talent construction as the core, constantly attracts talents and encourages innovation.
Here, you get not only a job, but also a platform to give full play to your potential and realize your personal value.